Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price & How to Invest
Last updated July 2026
Short answer
Arrowhead Pharmaceuticals (ARWR) is a clinical and now commercial-stage RNAi biotech whose siRNA drug plozasiran (REDEMPLO) won FDA approval in November 2025, making it a partnership-funded, catalyst-driven biopharma story rather than a steady-earnings compounder.
ARWR stock price
As of 2026-07-10, Arrowhead Pharmaceuticals, Inc. (ARWR) last closed at $76.40, up 317.3% over the past year. Over the past 52 weeks it has traded between $14.71 and $86.97.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Arrowhead Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Arrowhead Pharmaceuticals, Inc. (ARWR) do?
Arrowhead Pharmaceuticals is a biopharmaceutical company built around RNA interference (RNAi), using its TRiM (Targeted RNAi Molecule) platform to design small interfering RNA (siRNA) medicines that silence disease-causing genes in the liver and, increasingly, in tissues like the lung and muscle. Its lead drug, plozasiran (marketed as REDEMPLO), targets APOC3 to lower triglycerides and was approved by the U.S. FDA in November 2025 for familial chylomicronemia syndrome (FCS), with additional approvals in China, Canada, Australia, and the European Union. Behind it sits a broad pipeline spanning cardiometabolic disease, obesity, pulmonary, CNS, and muscle targets, several of which are partnered.
The investment picture is defined by large partnerships and lumpy, milestone-heavy revenue rather than steady product sales. A 2024-2025 global license and collaboration agreement with Sarepta Therapeutics brought roughly ~$825M in upfront value (about ~$500M cash plus ~$325M equity) and has since triggered nine-figure milestone payments, while Amgen (olpasiran for Lp(a)) and Novartis are additional partners. Those deals, plus capital raises, left Arrowhead with over ~$1.7B in cash resources as of early 2026, funding a long runway. Because much of the reported revenue is deal-driven, quarterly results swing sharply, and investors weigh the emerging REDEMPLO launch and late-stage readouts against continued operating losses in non-milestone quarters.
What's driving Arrowhead Pharmaceuticals, Inc. (ARWR)?
1. REDEMPLO (plozasiran) launch and label expansion
Plozasiran is now approved for FCS in the U.S., China, Canada, Australia, and the EU, giving Arrowhead its first commercial product. The larger commercial opportunity would come from broader indications like severe hypertriglyceridemia, where the addressable patient population is far bigger than the rare FCS setting.
2. Partnership economics
The Sarepta collaboration delivered roughly ~$825M in upfront value and has generated additional milestone payments (including ~$100M and ~$200M tranches reported in late 2025). Amgen's olpasiran and other partnered programs add royalty and milestone potential without Arrowhead bearing all the development cost, though the timing of these payments is uneven.
3. Broad RNAi pipeline beyond the liver
Arrowhead's TRiM platform extends siRNA delivery beyond hepatic targets toward lung, muscle, and CNS tissues, supporting candidates in cardiometabolic disease, obesity (such as ARO-INHBE), and pulmonary conditions. A deep, diversified pipeline gives multiple shots on goal but also spreads capital and clinical risk across many programs.
4. Strong balance sheet and runway
Following partner payments and equity offerings, Arrowhead reported total cash resources of roughly ~$1.78B in early 2026. That funding reduces near-term dilution pressure and lets the company advance late-stage trials and the REDEMPLO commercial build-out without immediate financing risk.
What are the risks to Arrowhead Pharmaceuticals, Inc. (ARWR)?
Arrowhead remains fundamentally a pipeline and partnership story, so revenue is lumpy and heavily dependent on milestone payments that do not recur each quarter, and the company posts operating losses in periods without such payments. The commercial uptake of REDEMPLO in the small FCS population is unproven, and broader label expansion depends on clinical and regulatory outcomes that can fail or slip. Competition in RNAi and lipid-lowering is intense from larger, better-capitalized rivals. Clinical trial setbacks, safety findings, regulatory delays, and partner decisions (including a partner pausing or returning a program) could all materially affect the stock, which is volatile like most clinical-stage biotech.
How is Arrowhead Pharmaceuticals, Inc. (ARWR) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Arrowhead Pharmaceuticals, Inc.'s investor relations page or your broker.
- Revenue (FY2025, ended Sept 2025): ~$829M
- Q1 FY2026 revenue (Oct-Dec 2025): ~$264M
- Q2 FY2026 revenue (Jan-Mar 2026): ~$74M
- Total cash resources (early 2026): ~$1.78B
- Sarepta deal upfront value: ~$825M (~$500M cash + ~$325M equity)
- Profitability: Milestone quarters profitable; loss-making without milestones
Arrowhead's reported revenue is dominated by partnership and milestone payments, which makes results swing dramatically between quarters (a large Q1 FY2026 milestone quarter versus a much smaller Q2). Traditional valuation multiples are of limited use for a company at this stage, so investors tend to focus on the REDEMPLO launch trajectory, pipeline readouts, cash runway, and deal flow rather than trailing earnings.
Who competes with Arrowhead Pharmaceuticals, Inc. (ARWR)?
RNAi and antisense specialists
Alnylam Pharmaceuticals and Ionis Pharmaceuticals are the most direct peers, both pioneers of RNA-based silencing medicines with approved products and deep pipelines that overlap Arrowhead in cardiometabolic and rare disease.
Lipid-lowering and cardiometabolic players
Novartis (inclisiran/Leqvio, an siRNA for cholesterol) and large pharma pursuing triglyceride and Lp(a) therapies compete in the same lipid space plozasiran and partnered programs target, often with far greater commercial scale.
Large partners and platform rivals
Amgen and Sarepta are partners rather than pure competitors, but big biopharma broadly competes for RNAi assets, talent, and the same disease markets, and can develop or license rival genetic medicines.
How to invest in Arrowhead Pharmaceuticals, Inc. (ARWR)
There are three common ways to get ARWR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ARWR sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where ARWR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Arrowhead Pharmaceuticals, Inc. (ARWR)
ARWR is a maturing RNAi platform company with a newly approved drug and large partner payments, but its revenue is lumpy and milestone-driven, so it trades on pipeline and deal catalysts more than on recurring profit.
More on Arrowhead Pharmaceuticals, Inc. (ARWR)
Whether ARWR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ARWR a buy?, and where the stock could go from here in the ARWR stock forecast.
For income investors, whether ARWR pays a dividend and how the payout looks is covered in does ARWR pay a dividend?
Build a basket around ARWR with Walnut
Use Arrowhead Pharmaceuticals, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Arrowhead Pharmaceuticals do?
+
Arrowhead develops RNA interference (RNAi) medicines using small interfering RNA (siRNA) to silence disease-causing genes. Its TRiM platform delivers these drugs to the liver and increasingly to other tissues, targeting cardiometabolic, rare, pulmonary, and muscle diseases.
Is ARWR profitable?
+
Arrowhead reports profits only in quarters with large partner milestone payments and posts operating losses otherwise. As of JULY 2026 its revenue is lumpy and deal-driven rather than coming from steady product sales, so it is not consistently profitable.
What is plozasiran (REDEMPLO)?
+
Plozasiran, marketed as REDEMPLO, is Arrowhead's lead siRNA drug that targets APOC3 to lower triglycerides. It won FDA approval in November 2025 for familial chylomicronemia syndrome (FCS) and has also been approved in China, Canada, Australia, and the EU.
What is the Sarepta partnership?
+
In late 2024, Arrowhead signed a global license and collaboration with Sarepta Therapeutics covering multiple clinical and preclinical siRNA programs. It carried roughly ~$825M in upfront value (about ~$500M cash plus ~$325M equity) and has triggered further nine-figure milestone payments.
How much cash does Arrowhead have?
+
As of early 2026, Arrowhead reported total cash resources of roughly ~$1.78B after partner payments and equity offerings. That gives it a substantial runway to fund late-stage trials and the REDEMPLO commercial launch.
Who are Arrowhead's main competitors?
+
The closest peers are RNAi and antisense specialists Alnylam and Ionis. In lipid-lowering it competes with Novartis (inclisiran) and other cardiometabolic developers, while large pharma broadly competes for RNAi assets and the same disease markets.
What are the biggest risks with ARWR?
+
Revenue is lumpy and milestone-dependent, the company loses money in non-milestone quarters, and REDEMPLO's commercial uptake is unproven. Clinical trial failures, regulatory delays, safety findings, competition, and partner decisions can all cause sharp stock moves typical of clinical-stage biotech.
How could an investor research ARWR?
+
Because ARWR is a catalyst-driven biotech, research tends to focus on the REDEMPLO launch, upcoming pipeline readouts, partnership milestones, and cash runway rather than trailing earnings multiples. Walnut is not an investment adviser, so treat this as descriptive information and do your own due diligence.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Arrowhead Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.